Samsung Semiconductor Europe Completes EMEA Headquarters Relocation to New Munich Office
18.11.2020 12:00:00 EET | Business Wire | Press release
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics. Co., Ltd. has announced today that the relocation of its EMEA headquarters from the Frankfurt region to Munich, a leading high-tech hub in Germany, is now completed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005044/en/
Samsung Semiconductor Europe at Bavaria Towers, Munich (Photo: Business Wire)
Aiming to be on the doorstep of many key customers and partners with whom the company is driving digital transformation across industries, Samsung Semiconductor Europe started moving into the new Bavaria Towers in early 2020. Consolidating the already existing Ismaning office along the way, the relocation process was finally completed by closing the previous location near Frankfurt by end of September.
“Faster response times to our customers and attracting the best talent in this technology hub are key for Samsung Semiconductor Europe to remain a leading solution provider for the next few decades,” said Dermot Ryan, managing director at Samsung Semiconductor Europe. “By embracing future trends like artificial intelligence (AI), 5G, internet of things (IoT), big data, cloud computing, automotive and more, we work at the chip and basic software level, not only to make our own devices more intelligent, but also to enable entire industries to become smarter. The move to Munich marks a new era for Samsung Semiconductor Europe as we embark upon a new age of innovation, cooperation and trust together with our employees, customers and partners.”
“As the state capital of Bavaria, Munich is not only an international and culturally diverse city in a beautiful environment, it is also Germany‘s foremost tech hub and one of the leading cities in digital transformation,“ says Clemens Baumgärtner, head of the Department of Labor and Economic Development, City of Munich. “Munich offers excellent infrastructure and a vibrant ecosystem of companies, universities, start-ups and professional networks to companies in the areas of high-tech, IoT and services. We are more than happy to welcome Samsung Semiconductor Europe to shape the future of our region together.”
Munich has not only a leading position within Germany’s ICT sector, with 119.000 employees and 11.300 companies in and around the area according to the Bavarian Statistical Office, it also ranks high within European ICT poles of excellence, according to a study of the European Commission.
At Bavaria Towers, Samsung Semiconductor Europe employs around 170 staff from a large variety of countries in sales and marketing for Samsung Electronics’ component business units in Europe, the Middle East and Africa along with its sales offices in Finland, France, Turkey and the UK. From a technology point of view, Samsung Semiconductor Europe provides component solutions featuring industry-leading technologies in the areas of memory, system LSI, foundry, LED and display, often setting a new standard in the industry.
The company also offers a dynamic work culture in an exciting and inspiring atmosphere. As employees’ health and safety are one of its top priorities, the company provides a variety of employee benefits for improved work-life balance and thrives on a diverse and empowering work environment.
To learn more about Samsung Semiconductor Europe, please visit https://www.linkedin.com/showcase/samsung-semi-europe/
###
About Samsung Semiconductor Europe GmbH
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics Co. Ltd., is headquartered in Munich, Germany and operates offices in Europe, Middle East and Africa (EMEA). Samsung Semiconductor's European base handles the marketing and sales of Samsung Electronics' component business units including Memory, System LSI, Foundry, LED and Display in EMEA for various applications including servers, data centres, mobile, industrial/automotive, IoT and more. For more information, please visit www.samsung.com/semiconductor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005044/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: ujeong.j@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom